Trial reportBritish journal of cancer2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer.
Trial report in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Review
- Sarcopenia and lower urinary tract diseases: links, mechanisms, and clinical implications.Frontiers in nutrition · 2025Review
- The impact of second-generation androgen receptor pathway inhibitors on skeletal muscle morphology and strategies to mitigate their effects in prostate cancer patients.Frontiers in rehabilitation sciences · 2025Review
- Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer.Prostate cancer · 2025Article
- Body composition in recurrent prostate cancer and the role of steroidogenic genotype.Endocrine-related cancer · 2024Article
- Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies.ESMO open · 2024Article
- A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Feasibility of home-based exercise training during adjuvant treatment for metastatic castrate-resistant prostate cancer patients treated with an androgen receptor pathway inhibitor (EXACT).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer.Prostate cancer and prostatic diseases · 2023Article
- Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration-resistant prostate cancer.Cancer medicine · 2023Article
- The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.PloS one · 2023Observational
- Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer.BJU international · 2021Article
- Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer.Prostate cancer and prostatic diseases · 2021Article
- Article
- Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2016Article
- Managing sarcopenia and its related-fractures to improve quality of life in geriatric populations.Aging and disease · 2014Review
- Article
- Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundStandard medical castration reduces muscle mass. We sought to characterize body composition changes in men undergoing maximal androgen suppression with and without exogenous gluocorticoids.
methodsCross-sectional areas of total fat, visceral fat and muscle were measured on serial CT scans in a post-hoc analysis of patients treated in Phase I/II trials with abiraterone followed by abiraterone and dexamethasone 0.5 mg daily. Linear mixed regression models were used to account for variations in time-on-treatment and baseline body mass index (BMI).
resultsFifty-five patients received a median of 7.5 months abiraterone followed by 5.4 months abiraterone and dexamethasone. Muscle loss was observed on single-agent abiraterone (maximal in patients with baseline BMI >30, -4.3%), but no further loss was observed after addition of dexamethasone. Loss of visceral fat was also observed on single-agent abiraterone, (baseline BMI >30 patients -19.6%). In contrast, addition of dexamethasone led to an increase in central visceral and total fat and BMI in all the patients.
interpretationMaximal androgen suppression was associated with loss of muscle and visceral fat. Addition of low dose dexamethasone resulted in significant increases in visceral and total fat. These changes could have important quality-of-life implications for men treated with abiraterone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.